Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
What will members gain?
Most viewed

PCSK9 Forum Inhibitors and Health Economics

The value of PCSK9 inhibition in very high risk patients is a Hot Topic in the light of recent data from the ODYSSEY OUTCOMES Economics Study. How do these data relate to the current clinical pathway used in the European setting?

PCSK9 Forum Editor Professor Anthony Wierzbicki (Guys and St. Thomas’ Hospital London, UK) puts the results in context.
Watch the video

Perspective on the ODYSSEY OUTCOMES Economic Study
Watch the video

PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
Watch the video

Hot Topics

Coronary artery calcium in familial hypercholesterolaemia

Coronary artery calcium may have a role in stratifying short-term risk in patients with familial hypercholesterolaemia (FH, inherited high cholesterol), according to a new study. This noninvasive approach may have value in targeting treatment with a PCSK9 inhibitor to those patients at highest risk.

Read the report

VIDEO: Is coronary artery calcium a risk assessment too in FH?
Watch the video

VIDEO: Severe FH: how to define?
Watch the video

VIDEO: ESC/EAS Task Force guidance for PCSK9 inhibitors
Watch the video

From the Editors

Did someone say “Beyond LDL-cholesterol”?

 

PCSK9 Forum Editor Professor John Chapman (Pitié-Salpétrière University Hospital, and Sorbonne University, Paris, France) discusses how ‘OMICS’ technologies could provide a precision medicine approach to managing non-LDL lipids.

 

Read the report

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology